Nitric Oxide-Based Medicine
We use our proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs.

Press Releases
-
March 2, 2021
Novan Bolsters Commercialization Expertise with Election of Steven D. Skolsky to Board of Directors
-
February 25, 2021
Novan Reports Full Year 2020 Financial Results and Provides Corporate Update
-
February 1, 2021
Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
